Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.
about
Exercise Prevention of Cardiovascular Disease in Breast Cancer SurvivorsSkeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin ChemotherapyLoss of urokinase receptor sensitizes cells to DNA damage and delays DNA repairVentricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant ChemotherapyCardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic trainingTriphenyl Phosphine-Functionalized Chitosan Nanoparticles Enhanced Antitumor Efficiency Through Targeted Delivery of Doxorubicin to Mitochondria.Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report.Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle.Doxorubicin chemotherapy affects intracellular and interstitial nitric oxide concentrations in skeletal muscle : Effect of doxorubicin on intracellular and interstitial NO in skeletal muscle.Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy.Effects of endurance exercise and doxorubicin on skeletal muscle myogenic regulatory factor expression.Creatine Supplementation and Doxorubicin-Induced Skeletal Muscle Dysfunction: An Ex Vivo Investigation.Effects of age on multidrug resistance protein expression and doxorubicin accumulation in cardiac and skeletal muscle.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscleRationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer
P2860
Q26785410-A0286DE5-46AC-49A6-B8A7-3D808EF622BAQ28548399-DEA5EE0B-620F-451A-9D6E-A4AE0FBA0AE4Q35200009-71FB6326-DE50-4DBA-8D72-259D673B0A11Q36558438-86712FD1-3DE7-41C4-B53C-FC0A7BFBFEC3Q37213203-60CC18F3-6686-466A-A57E-6BBD000D3710Q42255827-1B9090C6-36E0-449A-A2E9-7B2FC708080CQ42328053-6973B368-5F73-49EA-BDEB-2F3780298EB4Q42402464-D573EE0F-D097-406B-A6FE-F05924AFDC62Q44863433-3F80C41E-4933-44D7-A0CA-06E1B34D3ED7Q46778817-FA429E18-AD7D-4EF2-BEA9-D035BC9E0D73Q49184723-2326D6AF-4470-42CB-A26A-A51DF32B7882Q50785546-E5C52614-EE0B-4E1C-A5EC-9516A1397D80Q51192184-828DB7D4-18C1-43DA-B873-A983EB7F9022Q55222160-3C7FF276-3B10-49AC-8C39-30A95635F888Q57278903-94BF33D0-5E45-4C96-AD3E-20790A8C2231Q58768520-A17059F0-48A1-4873-94EA-828B72A45A23
P2860
Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Tissue retention of doxorubici ...... and skeletal muscle function.
@en
Tissue retention of doxorubici ...... and skeletal muscle function.
@nl
type
label
Tissue retention of doxorubici ...... and skeletal muscle function.
@en
Tissue retention of doxorubici ...... and skeletal muscle function.
@nl
prefLabel
Tissue retention of doxorubici ...... and skeletal muscle function.
@en
Tissue retention of doxorubici ...... and skeletal muscle function.
@nl
P2093
P2860
P1476
Tissue retention of doxorubici ...... and skeletal muscle function.
@en
P2093
David Hydock
Eric Bredahl
Noah Gibson
Reid Hayward
Stephanie Greufe
Traci Parry
P2860
P2888
P304
P356
10.1007/S13105-012-0200-0
P577
2012-08-14T00:00:00Z